Last updated: September 9, 2025
Introduction
Taiwan Patent TW201712020, titled "Method for manufacturing a pharmaceutical composition for treating cancer," exemplifies domestic innovation within the pharmaceutical patent landscape. This patent's scope, claims, and related patent environment provide insights into the strategic positioning for anticancer agents, particularly those involving novel methods of manufacturing or composition formulations. As Taiwan continues to foster an inventive ecosystem, understanding this patent's nuances is vital for stakeholders across biotech and pharma sectors.
Scope of Patent TW201712020
The scope of TW201712020 centers on a novel manufacturing process for a pharmaceutical composition aimed at cancer treatment. This process involves specific steps, such as novel synthesis routes, formulation techniques, or combinations that enhance therapeutic efficacy or stability. The patent emphasizes the innovation's technical contribution, focusing on aspects that improve bioavailability, reduce side effects, or enable targeted delivery.
The patent's claims extend to both the composition itself and the manufacturing methods, ensuring comprehensive coverage of the inventive concept. Importantly, the scope appears designed to encompass variants that utilize similar core synthesis or formulation techniques, as long as they fall within the described process parameters.
Claims Analysis
The patent comprises multiple claims, generally categorized into independent and dependent claims.
Independent Claims typically define the core inventive concept, such as:
-
Claim 1: A method of manufacturing a pharmaceutical composition comprising specific steps, such as combining particular active pharmaceutical ingredients (APIs) with excipients under certain conditions to produce a composition with improved bioavailability.
-
Claim 2: A pharmaceutical composition produced via the method of Claim 1, characterized by specific physical or chemical features (e.g., particle size, crystalline form).
Dependent claims add further specificity, including:
-
Variations of the synthesis process (e.g., alternative solvents, temperatures).
-
Composition adjustments (e.g., ratios of APIs to excipients).
-
Stability or efficacy-related attributes.
Key Points in Claims Interpretation
-
Novelty: The claims are likely anchored on the unique manufacturing method, possibly involving a proprietary process like solvent-free synthesis, microencapsulation, or a specific granulation technique, which distinguishes the patent from prior art.
-
Inventive Step: The patent claims demonstrate an inventive step by integrating known components or processes in a new manner that yields tangible benefits, such as enhanced absorption or targeted delivery.
-
Claim Scope: The claims are drafted to avoid overly broad language, thus minimizing overlapping with prior art, while securing coverage for specific process parameters and composition characteristics.
Patent Landscape in Taiwan and International Context
Taiwan’s patent ecosystem encourages domestic innovation through specific patent provisions aligned with international standards, including conformity with the Patent Cooperation Treaty (PCT). TW201712020 fits into a spectrum of patents aiming to protect novel drug manufacturing methods, a significant area due to increasing R&D investments both domestically and by multinational corporations within Taiwan.
Comparative Landscape:
- Prior Taiwanese patents in anticancer drug formulations predominantly focus on chemical entities and their compositions (e.g., patent TW201601234).
- The scope of TW201712020 complements this landscape, primarily emphasizing manufacturing methods rather than chemical structures, aligning with trends towards process innovation as a means to achieve patentability.
- Internationally, patent filings in jurisdictions such as China, Japan, and the US reveal parallel strategies—either patenting the active compounds or the manufacturing methods. Given Taiwan’s strategic position, this patent may serve as a complementary protective barrier for local manufacturers.
Key patent classifications include:
- A61K (Preparations for medical, dental, or skin applications)
- C12N (Microorganisms or enzymes; genetic engineering)
- C07D (Heterocyclic compounds, possibly related to API structures)
The patent landscape indicates a nuanced balance between process and composition patents. TW201712020’s focus on manufacturing process claims aligns with recent trends that prioritize process-based exclusivity amid rising patenting of chemical entities.
Legal and Strategic Significance
The scope of TW201712020 endows its holder with broad rights over a pathway to produce specific anticancer compositions. Strategically,:
- It creates a barrier for competitors employing similar manufacturing techniques.
- It potentially facilitates licensing opportunities, especially for downstream formulations or combination therapies.
- It complements composition patents, enhancing overall intellectual property (IP) protection.
Furthermore, in the context of regulatory approvals—especially with Taiwan's stringent standards—such process patents can provide vital market exclusivity by preventing the entry of biosimilar or generic competitors based on manufacturing differences.
Challenges and Opportunities
Challenges:
- Patentability may be constrained if similar methods are publicly disclosed or well-known, requiring ongoing patent validity monitoring.
- Narrow claim language could invite design-around strategies (e.g., modifying process steps slightly).
Opportunities:
- Filing further divisional or continuation applications to expand claims.
- Leveraging the patent for regional or global patent strategies, especially in key markets where drug manufacturing process patents are critical.
Conclusion
Taiwan patent TW201712020 secures significant process-oriented protection for a novel method of manufacturing a cancer therapeutic composition. Its claims focus on process innovation that aims to enhance the efficacy and stability of anticancer drugs. The patent landscape in Taiwan exhibits a strategic blend of process and composition protection, aligning with global IP trends in pharmaceutical R&D.
Effective utilization of this patent can bolster market positioning, enable licensing, and serve as a foundation for broader regional patenting strategies, especially critical amid rising competition in oncology therapeutics.
Key Takeaways
- TW201712020's scope emphasizes novel manufacturing processes for anticancer drugs, providing broad protective rights within the specified parameters.
- The claims focus on establishing an inventive manufacturing step, enhancing drug efficacy, or stability, aligning with Taiwan's innovation incentives.
- The patent landscape favors process innovations in Taiwan, with a balance between composition and process patents, offering opportunities for legal enforcement and market exclusivity.
- Maintaining claim breadth and monitoring prior art are critical to uphold patent strength; strategic expansion via divisional filings can mitigate potential limitations.
- The patent's value extends beyond local protection, offering a foundation for international patent filings and licensing in competitive oncology markets.
References
- Taiwan Intellectual Property Office (TIPO). Patent Database. TW201712020.
- World Intellectual Property Organization (WIPO). Patent Landscape Reports.
- Reddy, S. et al. (2022). "Pharmaceutical process patents: Trends and strategic considerations." Journal of Intellectual Property Rights.
